RxDoctor Payments Data

Clarence Tam, MD

Ophthalmology · Fond du Lac, WINPI 1447365960

Payments from drug & device makers

$1,526in general payments, 2019–2025

Across 32 payments — averaging $47.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$695
  • Sight Sciences, Inc.$241
  • Glaukos Corporation$201
  • AbbVie$142
  • The Cameron-ehlen Group, Inc.$118
  • Ocular Therapeutix, Inc.$73
  • plus $55 from 3 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$1,49498%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,526 in reported general payments places this provider in the 70th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$150,914
Medicare patients
298
Services billed
1,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate178$13,884
RestasisCyclosporine21$12,186
Cyclosporine23$9,840
VyzultaLatanoprostene Bunod18$8,920
RhopressaNetarsudil Mesylate20$7,685
Latanoprost378$4,238
CombiganBrimonidine Tartrate/Timolol17$3,894
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat159$2,821
Timolol Maleate175$2,799
Loteprednol Etabonate18$2,291
Brimonidine Tartrate108$2,050
Atropine Sulfate22$895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$142$16,08038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Fond du Lac

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →